An Indian businessman not on the FIR (First Information Report), not charged with anything, and not even formally a suspect, has spent months being publicly associated with a major counterfeit-pharmaceutical investigation. The case of Swapnadip Roy raises a broader question about the gap that can emerge between the official record and the public narrative surrounding high-profile criminal investigations.
Some media controversies arise from competing sets of established facts. This one appears to involve the widening distance between what has formally been recorded and what has been publicly alleged. For Roy, a businessman based in Dubai, that gap has become central to the story itself.
The allegations and descriptions attached to his name over recent months have been serious. Yet the available documentary record presents a considerably narrower picture than the one that emerged in public reporting.
What the Official Record Says About Roy
FIR No. 0075, registered by the Economic Offences Wing (EOW) on 3 June 2025, names three accused in connection with the counterfeit Ozempic matter: Vicky Ramancha, R&R Global Procurement Corp., and R&R Premier Medical Equipments Trading LLC.
Roy is not among those named accused. He occupies no formal procedural role in the FIR.
The only known reference to him in official investigative material appears in a September 2025 EOW status report, which states that his name “has surfaced” and that his alleged role “is being ascertained.” The report itself describes the investigation as remaining at a preliminary stage.
No charge has been filed against Roy. No authority has formally described him as a mastermind, a key accused, or a central figure in the matter.
That is the known documentary position. Much of the wider public narrative appears to have developed outside it.
How the Public Narrative Evolved
Between January and May 2026, several reports in major Indian publications described Roy in substantially stronger terms than those reflected in publicly available investigative documents.
A Pioneer article published on 27 January 2026 described him as “actually running the show” and “the key architect” of the alleged fraud, while also stating that he had been added as an accused in the FIR.
A Hindustan Times report on 4 February framed the counterfeit-Ozempic matter as involving Roy directly.
Subsequent reports in The Pioneer and The Times of India in May 2026 referred to him as an “alleged mastermind” and a “key accused,” citing unnamed sources.
The descriptions attributed to Roy in those reports appear to extend beyond what is reflected in the FIR and in the publicly available language of the EOW status report.
Across that period, the legal position publicly associated with Roy does not appear to have materially changed. The public descriptions, however, became progressively stronger.
The Origin of the Allegations
Questions surrounding the origin of those allegations have also become part of the dispute.
According to materials reviewed in connection with Roy’s account of events, statements linking him to the matter were made by Vicky Ramancha, who is named as an accused in the FIR.
Ramancha later reportedly withdrew or altered aspects of those statements during recorded conversations dated 30 January and 2 February 2026. According to Roy’s account of those conversations, Ramancha stated that no evidence linked him to the alleged fraud.
Ramancha subsequently characterized earlier statements as having been made under duress.
The competing explanations have not been tested in court. However, they form an important part of the chronology surrounding how Roy became publicly associated with the case.
Roy’s position is that the allegations emerged after he declined repeated requests for financial assistance relating to legal expenses. According to his account, the public allegations followed those refusals.
If accurate, that sequence of events may raise questions about motive. At present, however, the competing accounts remain disputed.
The Corporate Timeline
Corporate documents reviewed in relation to the matter also appear to bear directly on the timeline.
R&R Premier Medical Equipments Trading LLC, one of the entities named in FIR No. 0075, was sold by Roy to Ramancha on 20 March 2023 pursuant to a Company Takeover Agreement.
According to those documents, Roy ceased from that date to hold ownership or managerial involvement in the company.
The conduct underlying the FIR reportedly began in September 2023, approximately six months after the transfer took place.
If the timeline reflected in those documents is accurate, it creates an issue that sits near the center of the dispute: the activities under investigation appear to post-date Roy’s involvement with the company.
That question has become particularly significant because some reports sought to connect him to events through the same corporate entity.
The Distinction That Remains Important
Roy has not been named as an accused in FIR No. 0075. No charges have been publicly filed against him. The publicly available status report language does not appear to assign him a formal role beyond noting that his name had surfaced during inquiries.
At the same time, public reporting has at various points described him in terms substantially more severe than the documentary record itself appears to support.
Whether future investigative developments change that position remains a matter for authorities rather than headlines.
For now, the distinction remains significant: one record consists of formal investigative documents; the other consists of public allegations and anonymous sourcing.
The difference between those two things may ultimately be the central issue in Roy’s case.
